Axon Enterprise (NASDAQ:AXON) PT Raised to $441.00 at The Goldman Sachs Group

Axon Enterprise (NASDAQ:AXON) had its price objective increased by The Goldman Sachs Group from $385.00 to $441.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

AXON has been the topic of a number of other research reports. Robert W. Baird raised their price target on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target on the stock. Northland Securities increased their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective on the stock. Finally, JMP Securities upped their target price on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $382.85.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $444.52 on Wednesday. The firm has a market capitalization of $33.55 billion, a P/E ratio of 129.98, a PEG ratio of 12.05 and a beta of 0.94. The business has a 50-day moving average of $396.09 and a 200-day moving average of $336.52. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise has a 1 year low of $199.29 and a 1 year high of $455.17.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business’s quarterly revenue was up 34.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.80 earnings per share. On average, equities analysts anticipate that Axon Enterprise will post 1.79 EPS for the current year.

Insider Activity

In related news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the transaction, the chief executive officer now directly owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the sale, the director now directly owns 4,892 shares in the company, valued at approximately $1,783,916.72. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the transaction, the chief executive officer now directly owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 371,172 shares of company stock valued at $137,000,162. 6.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AXON. PFG Investments LLC lifted its holdings in Axon Enterprise by 0.6% during the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after purchasing an additional 25 shares during the last quarter. Mather Group LLC. lifted its stake in shares of Axon Enterprise by 3.7% during the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after buying an additional 27 shares during the last quarter. CWM LLC lifted its stake in shares of Axon Enterprise by 1.3% during the 3rd quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock worth $1,141,000 after buying an additional 36 shares during the last quarter. SPC Financial Inc. grew its stake in Axon Enterprise by 2.2% in the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after buying an additional 38 shares during the last quarter. Finally, Dorsey Wright & Associates raised its holdings in Axon Enterprise by 0.3% in the 2nd quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after acquiring an additional 39 shares during the period. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.